Summary Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs.The company’s research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist.
It conducts research in the therapeutic areas of oncology, immune inflammation and metabolic disorders such as diabetes and obesity.Rhizen Pharma’s products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others.
It collaborates with other pharmaceutical companies. Rhizen is headquartered in La Chaux-de-Fonds, Switzerland.
Rhizen Pharmaceuticals SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The Global Gene Editing Partnering Terms and Agreements 2010-2021 report provides an understanding and access to the gene editing partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in gene editng partnering deals Disclosed headlines, upfronts, milestones and royalties...
The global pharmaceutical filtration market reached a value of US$ 9.05 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 29.7 Billion by 2027, exhibiting a CAGR of 22.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect...
The global fermented ingredients market reached a value of US$ 23.1 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 39.3 Billion by 2027, exhibiting a CAGR of 9.3% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Ricinoleic Acid Market 2022-2026 The analyst has been monitoring the ricinoleic acid market and it is poised to grow by $ 90.64 mn during 2022-2026, accelerating at a CAGR of 4.52% during the forecast period. Our report on the ricinoleic acid market provides a holistic analysis, market size and forecast, trends,...
The global seaweed market reached a value of US$ 6.73 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 12.85 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the...
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of distribution agreements from...
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2022 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments. This report provides details of the latest partnering...
Primary Sclerosing Cholangitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 22.214.171.124) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Cyclin Dependent Kinase 4 - Drugs In Development,...
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.